Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Rocky, I'm not payin funken an arm and a leg for that vacine

<< Previous

Bullboard Posts

Next >>

Post by luvhorseson Nov 09, 2020 10:49am

137 Views

Post# 31862629

Rocky, I'm not payin funken an arm and a leg for that vacine

...I bet you dollars to donuts that they will come back and say that there as been an error in their reporting.....comm'on...90%??? Plus the timing of the release....after Trump got dumped!!!

I think there's something fishy here...unfortunately, it has killed c.AGN and c.SONA and others as well :(

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market